Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
Date:4/30/2009

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2009 financial results after the market closes on Thursday, May 7, 2009.

Cadence management will host a conference call and live webcast to discuss the financial results on Thursday, May 7, 2009 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 877-856-1961 (domestic) or 719-325-4792 (international). To access the webcast, please visit the company's website at and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
9. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to ... as drinking more water or limiting their exposure to the sun, according to a ... beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ...
(Date:12/6/2016)... ... December 06, 2016 , ... An inventor, from Talladega, Ala., thought there ... she invented the patent-pending SLING-VEST. , The SLING-VEST provides an effective way to support ... to traditional slings. As a result, it helps to reduce discomfort and shifting. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health insights for population health management, announces today a strategic relationship with ... CitiusTech’s cloud-hosted clinical rules engine that offers advanced Clinical Quality Measures (CQM) ...
(Date:12/6/2016)... ... December 06, 2016 , ... It ... Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to check out ... resource. The expo’s beneficiary this year was Crossroads, a fully-accredited gender-responsive treatment ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new ... after launch. Almost 200 backers pledged more than $25,000 on Kickstarter ... , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... 340B (AIR 340B) projects the 340B Drug Pricing Program will ... which time it is expected to exceed $23 billion in ... see 340B purchases surpass current Medicare Part B drug reimbursement ... new study – based on analysis of data on total ...
Breaking Medicine Technology: